Elizabeth Holmes is reportedly plotting a new Theranos from behind bars

The fall of Elizabeth Holmes, once heralded as the "next Steve Jobs" of the biotech industry, serves as one of the most significant cautionary tales in the history of Silicon Valley. Now, nearly three years after she began serving an 11-year prison sentence for her role in the massive fraud that brought down Theranos, new evidence suggests that the disgraced entrepreneur remains focused on the industry that defined her rise and subsequent downfall.

A surprise documentary titled "You Can See Everything," directed by Lance Oppenheim and executive produced by comedian Nathan Fielder, premiered at the Telluride Film Festival to significant critical attention. The film, which chronicles three years of the lives of Holmes and her partner, Billy Evans, provides an intimate, often unsettling look at a couple preparing for a lengthy separation while allegedly laying the groundwork for a business venture described by insiders as "Theranos 2.0."

The Genesis of the New Venture

The documentary captures a critical window of time, beginning 34 days before Holmes reported to a federal prison camp in Bryan, Texas, in May 2023. Through fly-on-the-wall footage, the directors document several candid conversations between Holmes and Evans. In these scenes, the couple is shown engaging in discussions with potential business partners, strategizing the launch of a new medical technology firm.

According to reports emerging from the screening, Evans has expressed a clear intention to spearhead the development of this new entity while Holmes remains incarcerated. The project is being framed not as a clean break from her past, but rather as an evolution of the vision she once touted at Theranos—a claim that has sparked immediate debate among legal experts, investors, and industry ethicists regarding the feasibility and appropriateness of a "second act" for a convicted fraudster.

A Chronology of the Theranos Saga

To understand the weight of these new developments, one must look back at the meteoric rise and catastrophic collapse of the original Theranos enterprise:

• 2003: Elizabeth Holmes drops out of Stanford University at the age of 19 to found Theranos, with the stated goal of revolutionizing blood testing through proprietary, miniaturized technology.
• 2013-2014: Theranos enters a high-profile retail partnership with Walgreens and hits its peak valuation of $9 billion. Holmes is featured on the covers of major business publications, heralded as a self-made billionaire.
• 2015: The Wall Street Journal publishes a landmark investigative report by John Carreyrou, revealing that the company’s "Edison" machines were not functioning as claimed and that the company was relying on third-party commercial analyzers.
• 2016: Forbes downgrades its valuation of Holmes from $4.5 billion to zero. The SEC, CMS, and Department of Justice launch formal investigations.
• 2018: Theranos formally dissolves. Holmes and former COO Ramesh "Sunny" Balwani are indicted on multiple counts of wire fraud and conspiracy.
• 2022: A jury finds Holmes guilty on four counts of defrauding investors. She is subsequently sentenced to 11.25 years in federal prison.
• 2026: The documentary "You Can See Everything" brings public attention back to Holmes’s post-conviction activities.

Financial Context and Investor Impact

The sheer scale of the fraud perpetrated by Theranos is difficult to overstate. In its peak years, the company raised approximately $900 million from a roster of high-profile investors, including media mogul Rupert Murdoch, the Walton family (heirs to the Walmart fortune), and former Secretary of Education Betsy DeVos. These investors were sold on the promise of a "lab-in-a-box" that could diagnose hundreds of diseases from a single drop of blood.

The discovery that the technology was non-existent resulted in total losses for these private investors. While the new project led by Billy Evans remains in the early stages, the mere association with Holmes carries a significant "reputational tax." Investors in the biotech space, which relies heavily on trust and rigorous peer-reviewed validation, remain skeptical that any entity associated with Holmes could regain the necessary regulatory approval or venture capital support.

Legal and Ethical Implications

Legal analysts have noted that while Holmes is barred from holding certain positions as a result of her conviction, she is not legally prohibited from advising on business strategies, provided they do not violate the terms of her incarceration or involve further fraudulent activity. However, the optics of such a venture are fraught with complexity.

"The public interest in this case stems from the audacity of the original fraud," says a legal consultant familiar with white-collar crime. "If there is any attempt to replicate the Theranos model—even if the underlying science were somehow made legitimate—the barrier to entry for someone with her track record is effectively insurmountable."

Furthermore, the involvement of Billy Evans, who is not a convicted party, complicates the legal landscape. If the business is structured primarily under his name, it may bypass some of the regulatory restrictions that apply directly to Holmes. Nevertheless, the scrutiny from the SEC and other oversight bodies is likely to be absolute should the company attempt to solicit funds from the public or institutional markets.

Reaction and Public Sentiment

The trailer for "You Can See Everything" has generated a "tremendous amount of buzz," primarily due to the stark, unfiltered nature of the footage. Audiences are confronted with the reality of a woman who, despite being a convicted felon, is shown negotiating future business deals from her living room while the clock toward her prison term ticks down.

Reaction from the scientific community has been uniformly cautious. Many researchers who spent years debunking the original Theranos claims have voiced concern that any "Theranos 2.0" would be met with extreme hostility by the FDA and the medical community at large. The consensus is that the brand of "stealth innovation" practiced by Holmes is fundamentally incompatible with the modern requirements for clinical trial transparency and patient safety.

The Broader Impact on Silicon Valley

The Theranos affair fundamentally altered the relationship between Silicon Valley venture capitalists and the companies they fund. The era of "fake it until you make it" has faced a reckoning. Increased due diligence, the requirement for board-level scientific advisory committees, and a shift toward tangible, peer-reviewed data have become the new standards in biotech investing.

The emergence of a documentary highlighting Holmes’s continued business ambitions serves as a reminder that the trauma of the Theranos collapse is still fresh. Whether or not the new venture reaches the point of actual product development, its existence forces a conversation about accountability in the tech sector.

As the industry moves toward more rigorous standards, the story of Elizabeth Holmes remains a peripheral but persistent shadow. The documentary "You Can See Everything" is not merely a portrait of a person in the midst of a life-altering transition; it is a clinical observation of how the motivations that lead to catastrophe are often the very same ones that drive an individual forward, regardless of the consequences. As the film makes its rounds in the festival circuit, it invites the public to decide whether they are witnessing a genuine attempt at redemption, or a final, desperate act of a narrative that has already been told.